SEMAGLUTIDE

Dose per Vial/Cartridge

Latest Research

Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial.

2026 Jun

Sharma PK, Redkar SV, Madhav Karmalkar A, Anand S, Patil VS, Nurulhasan AR, Manan Bharatkumar P, Barge V, Shah SJ, Patel CB, Choudhary A, Sudheer K, Rambabu K, Narasinga Rao S, Swapna M, Ankathi SK, Singh VB, Sarkar G, Gautam SK, Das KK, Bhattacharya R, Tripathi KN, Sudarsi B, Parmar D, Kansagra K, Pathak H

Open

Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.

2026 Apr 30

Abraham R, Foong D, Piya M, Grudzinskas K, Ho V

Open

In brief: Rybelsus R2 rebranded as Ozempic.

2026 Apr 13

Authors unavailable

Open

Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting.

2026 Apr 9

Ali SH, Lee MH, Tan KXQ, Wong CJ, Magkos F, Ang IYH, Toh SA

Open

Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report.

2026 Apr 6

Keles A, Sari K, Giray E, Illeez OG

Open

Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.

2026 Apr

Alqinai B, Adeniran O, Adekolu A, Gayam S

Open

The "Ozempic® Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals with Lower Limb Amputation - Case Report.

2026 Mar 26

Bykowski J, Loewen G, Loewen B, Seslija D

Open

Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.

2026

Yu Z, Fu D, Xu J, Lin C, Yin G, Cai D, Jiang H, Ling K, Chen J, Zhuo Y

Open

Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.

2026

Parizad R, Hatwal J, Taban Sadeghi M, Brar A, Desai R, Batta A, Mohan B

Open

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.

2026

van Kleef LA, Michel M, Savas M, Pustjens J, Theel W, van Rossum EFC, Paik JM, Younossi ZM, Janssen HLA, Labenz C, Schattenberg JM, Brouwer WP

Open